Vaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by Swiss National Bank

Swiss National Bank boosted its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 21.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 219,000 shares of the company’s stock after acquiring an additional 38,400 shares during the period. Swiss National Bank owned 0.18% of Vaxcyte worth $17,927,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC acquired a new position in Vaxcyte in the 4th quarter valued at about $28,000. Smartleaf Asset Management LLC increased its position in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after acquiring an additional 260 shares during the period. Meeder Asset Management Inc. increased its position in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock valued at $80,000 after acquiring an additional 635 shares during the period. Blue Trust Inc. increased its position in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after acquiring an additional 371 shares during the period. Finally, Assetmark Inc. increased its position in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after acquiring an additional 775 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Activity at Vaxcyte

In related news, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. This represents a 46.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the sale, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. The trade was a 4.91 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,250 shares of company stock valued at $3,840,018. 3.10% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on PCVX. Guggenheim reiterated a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. The Goldman Sachs Group began coverage on Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and set a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $147.50.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $74.72 on Wednesday. The business’s 50 day simple moving average is $81.77 and its 200-day simple moving average is $94.41. The firm has a market capitalization of $9.62 billion, a price-to-earnings ratio of -16.24 and a beta of 1.02. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.